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 Introduction 
 Preeclampsia is a common syndrome and remains a 
major cause of maternal and fetal morbidity and mortal-
ity  [1, 2] . Most women develop the late-onset syndrome 
with normal fetal growth, whereas a smaller subset devel-
ops the early-onset syndrome usually accompanied by 
intrauterine growth restriction (IUGR)  [3, 4] . Both types 
of the syndrome are characterized by systemic inflam-
mation that resolves following delivery. Since trophoblast 
fragments and proteins, microvillous membranes and 
cell-free fetal DNA are all detectable in higher amounts 
in maternal blood of preeclamptic women, the placenta is 
the likely source of this inflammatory disorder  [3] .
 The prevention of preeclampsia remains a consider-
able challenge in obstetrics. Neither low-dose aspirin  [5] 
nor antioxidant vitamins  [6, 7] were shown to be helpful 
in preventing any type (early- or late-onset) of preeclamp-
sia. One reason why preventive strategies for this syn-
drome have proven so disappointing at present is that the 
proposed interventions have commenced in the mid to 
late second trimester, when the underlying placental dis-
order triggering the syndrome may already be estab-
lished. Thus, novel biomarkers of the syndrome expressed 
in the first trimester to predict pregnancies at risk may 
permit new interventions to try and prevent this placen-
tally mediated syndrome.
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 Abstract 
 Objective: To determine maternal serum placental protein 
13 (PP13) in normal pregnancy and preeclampsia.  Methods: 
A prospective, longitudinal study with 41 normal pregnant 
women, 18 cases with preterm delivery or cervix insufficien-
cy and 4 with developing late-onset preeclampsia. Six hun-
dred and sixty-six maternal blood samples were obtained 
every 2–4 weeks starting at 5–8 weeks gestation (10–12 sam-
ples/patient) and tested for serum PP13 by ELISA.  Results: In 
normal pregnant women delivering at term, median mater-
nal serum PP13 levels were growing from 166 to 202 pg/ml 
and 382 pg/ml in the first, second and third trimester, re-
spectively. Preeclamptic women had significantly reduced 
PP13 levels in the first trimester (multiples of median of 0.14 
at 7–8 weeks; p = 0.005 compared to normal). PP13 in the 
third trimester was significantly higher compared to normal 
at 35–36 weeks with PP13 multiples of median of 1.79.  Con-
clusion: This preliminary study indicates that low levels of 
PP13 in early pregnancy identify at-risk pregnancies, where-
as high levels precede the syndrome in late pregnancy and 
suggest syncytiotrophoblast necrosis. 
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 Recently, the concentrations of placental protein 13 
(PP13)  [8] were shown to be altered in maternal blood in 
pregnancy disorders such as preeclampsia  [9] . More re-
cent studies have shown that the serum levels of PP13 are 
significantly reduced at 11 to 13  8 6 weeks in cases de-
veloping early- as well as late-onset preeclampsia  [10, 11] . 
On the background of these data, we analyzed cases de-
veloping late-onset preeclampsia longitudinally through-
out their pregnancies. PP13 is expressed in the placental 
syncytiotrophoblast, and its levels in maternal blood may 
reflect turnover and integrity of this layer. Our data sug-
gest a biphasic alteration in maternal expression of PP13 
during the evolution of pregnancies that ultimately de-
velop preeclampsia.
 Materials and Methods 
 Study Design and Population 
 The prospective study involved the Women’s Hospital at the 
University of Zurich, Switzerland and a collective of doctors in 
private practice at Nordhorn, Germany. The study was approved 
by the ethical committees of both centers and women were en-
rolled after providing informed consent. Patients were followed 
from the first positive   -hCG test at enrolment throughout ante-
natal visits during pregnancy until delivery, and outcome was 
documented in the early postpartum period. Five-milliliter ali-
quots of blood were provided every 2–4 weeks from enrolment 
until 5–15 weeks after delivery. Serum was stored frozen at –70 ° C 
until tested. Demography, maternal medical history, results of 
blood pressure measurements, urinalyses and laboratory tests 
were collected and recorded within an electronic database, as 
were the later pregnancy outcomes ( table 1 ).
 Women aged 18–45 years with a singleton gestation who de-
livered after 20 weeks were included in the current study. The to-
tal number of patients enrolled was 92, of which 19 were excluded 
due to missed abortions or incompliance (no blood or loss of fol-
low-up). Ten patients with multiple admissions of tocolytic agents 
were excluded due to tocolytic effects on PP13 serum levels dis-
covered post factum, which will be reported elsewhere [Huppertz, 
pers. commun.]. Accordingly, the current report describes the re-
sults obtained from 63 patients, 4 of them preeclamptic and 59 
unaffected. The 4 patients who developed preeclampsia corre-
spond to 4.5%, as expected from previous epidemiological re-
ports, and the 59 unaffected patients are subdivided into 41 with 
normal outcome, 8 who delivered preterm ( ! 37 weeks) and 10 
with short cervix (length  ! 25 mm, according to the American 
College of Obstetricians and Gynecologists)  [12] . None of the pre-
term cases was complicated by preterm preeclampsia.
 Preeclampsia was defined according to the classification of the 
International Society for the Study of Hypertension in Pregnancy 
 [13, 14] , namely hypertension that developed after 20 weeks in a 
previously normotensive woman and was coupled to proteinuria 
exceeding 300 mg in 24-hour collections or 2+ in dipstick testing. 
A total of 664 blood samples (10–12 of each patient) were obtained 
from the 59 unaffected women and the 4 preeclamptic patients.
 PP13 Testing 
 Maternal serum concentration of PP13 was measured blinded 
to pregnancy outcome using a solid-phase sandwich ELISA with 
a pair of PP13-specific monoclonal antibodies, marked with am-
plified biotin-extravidin-horseradish-peroxidase complex and 
developed with tetramethylbenzidene substrate, as previously de-
scribed  [9, 10] . Optical density was measured at 450 nm against a 
650-nm background and translated to a quantitative amount by 
using a calibration curve made of recombinant PP13 standards 
(0–500 pg/ml). The assay’s operating range is 5–400 pg/ml, and 
samples with lower readings were assigned the value 5 pg/ml. The 
intra- and interassay coefficients of variation for this study were 
5.3 and 9.5%, respectively, while the recovery coefficient of varia-
tion was 11.5%.
 Statistical Analysis 
 Baseline and delivery characteristics were compared between 
cases and controls using the Fisher exact test for categorical vari-
ables and independent t tests for continuous variables.
 PP13 levels were not normally distributed; therefore, we com-
pared PP13 levels across the 2 outcome groups using the Wilcox-
on rank sum test. PP13 levels increased with gestational age. To 
take this effect into account, PP13 levels were converted to mul-
tiples of the normal median (MoM) for the controls at the same 
gestational age, based on a weighted (by number of cases) regres-
sion of the observed median at each completed week. We exam-
ined other major confounders: PP13 did not change with body 
mass index (p = 0.168), age (p = 0.737), parity (p = 0.147) and eth-
nicity (p = 0.606). Thus, the calculation of MoM was not further 
adjusted to these confounders.
 Immunohistochemistry 
 Term placentas from normal (n = 5) and late-onset preeclamp-
sia (n = 5) cases were obtained from the Women’s Hospital of 
Aachen University, Germany and the Wolfson Medical Centre in 
Holon, Israel at the time of this study after obtaining informed 
consent and the placentas were then used for immunohistochem-
istry. These 10 cases were not related to the cases tested for serum 
PP13.
 A tissue block of each placenta was fixed in 4% formaldehyde, 
dehydrated in a graded series of ethanol and embedded in paraf-
fin. Five-micrometer sections were cut, mounted on glass slides 
and deparaffinized. Immunohistochemical staining was per-
formed with monoclonal primary antibodies against PP13 (mono-
clonal antibodies 27-2-3 and 215-28-3) at a dilution of 1: 10. Posi-
tive staining appeared red after using a standardized staining
sequence based on the horseradish peroxidase-linked streptavi-
din-biotin technique for the detection of a biotinylated secondary 
antibody and AEC detection reagent. Control reactions excluded 
the use of primary antibodies or made use of a negative control 
antibody (DAK-GO1; Dako) and were always negative.
 Results 
 Demography and Delivery Characteristics 
 Table 1 displays the baseline and delivery characteris-
tics in relation to pregnancy outcome. Women were of 
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similar age at enrolment (31  8 5, 33  8 7 and 30  8 4 years 
for normal control, unaffected and preeclamptic women, 
respectively) and were enrolled at a similar gestational 
age (7.8  8 2.2, 6.8  8 2.7 and 9.1  8 2.1 weeks, respec-
tively). About 60% of the enrollees were Caucasian in ei-
ther group. The preeclamptic and normal outcome group 
women delivered at term; delivery of the unaffected group 
was lower due to the patients who delivered preterm (35.2 
 8 1.4 weeks). All preeclamptic patients delivered by vag-
inal delivery (80% in the normal outcome group and 70% 
in the unaffected group in which 6/8 preterm cases and 
4/10 short cervix cases delivered by caesarean section). 
Baby birth weight was similar in the control group (3,446 
 8 417 g) compared to the preeclamptic group (3,300  8 
728 g), but lower in the unaffected group (3,017  8 547 g) 
due to the preterm delivery cases (2,100  8 330 g).
 At enrolment, all patients had normal blood pressure 
and none or traces of proteinuria. At 35  8 3 weeks, both 
systolic and diastolic blood pressure of preeclamptic pa-
tients were elevated above 140/90 with proteinuria of 2+ 
(95% CI: 2+ to 4+). 
 PP13 Blood Levels 
 Following each individual patient with normal out-
come, it was discovered that their values did not change 
much during the first trimester, although fluctuations 
around the median values indicated a tendency towards 
higher values near the time that pregnancy was estab-
lished by the   -hCG test and at the end of the first tri-
mester ( fig. 1 a, solid line). For each individual patient, 
the values were on average 25% higher in the second tri-
mester and approximately double this amount towards 
term at around 35–36 weeks. At 8–12 weeks after deliv-
ery (corresponding to 41–45 and 46–50 weeks from the 
last menstrual period), PP13 disappeared from the ma-
ternal serum ( fig. 1 a, solid line), thus enabling us to use 
this as a baseline to correct the values of each individual 
woman. This approach improved the accuracy of the 
analysis.
 To obtain the cross-section of the 41 normal patients 
(430 blood samples), median PP13 values with 95% CI 
were calculated ( table 2 ). Median first trimester PP13 lev-
el adjusted to gestational week after weighted (by number 
of patients) regression was 166 pg/ml (range 126–202). 
The median second trimester level adjusted to gestation-
al age was 202 pg/ml (range 171–233), reflecting an aver-
age increase of 25% between the first and the second tri-
mester. Values for individuals increased 50–100% from 
the first trimester to the maximum value reached during 
the third trimester. PP13 disappeared from maternal 
blood after delivery, indicating that serum PP13 is direct-
ly related to pregnancy and the presence of the placenta 
( table 2 ;  fig. 1 a, solid line).
 Comparison of the normal group to the total unaf-
fected group [including cases that subsequently delivered 
preterm or those with a relatively shorter cervix ( fig. 1 a, 
triangles)] indicated that the normal and unaffected 
women almost overlap and the differences were not sig-
nificant throughout pregnancy ( table 2 ).
 In contrast to the above, the level of PP13 in pre-
eclampsia cases (51 blood samples collected from 4 pa-
tients) started lower than normal ( fig. 1 a, dashed line). 
Normal
(n = 41)
Unaffected
(n = 59)
PE
(n = 4)
Maternal age at enrolment, years 3185 3387 3084
GA at enrolment, weeks 7.882.2 6.882.7 9.182.1
Caucasians, % 60 58 50
Nulliparous, % 41 44 50
More than 1 pregnancy loss/abortion, % 32 32 50
Smoking, % 24 27 0
Blood pressure at enrolment, mm Hg ≤110/73 ≤107/81 ≤140/90
Elevated blood pressure at GA, weeks – – 35.083.0
Proteinuria (dipstick) traces traces 2+ (2+ to 4+)
GA at delivery, weeks 39.981.1 38.281.7 38.581.1
Birth weight, g 3,4468417 3,0178547 3,3008728
Vaginal delivery, % 80 75 100
Values are medians 8 95% CI.
PE = Late-onset preeclampsia; GA = gestational age.
Table 1. Demographic characteristics
of women in the 3 groups (control,
unaffected and late-onset preeclampsia)
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Although differences between individuals occurred, all 
individuals had very low PP13 values during the period 
of gestational age 5–15 weeks with median values of 35 
and 46 pg/ml for gestational age 5–10 and 11–15 weeks, 
respectively, with p  ! 0.001 and 0.01, respectively, com-
pared to normal cases of the corresponding gestational 
age ( table 2 ;  fig. 1 a, dashed line). The standard deviation 
in this group was very small. In fact, for the very early 
0
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Weeks after last menstruation
PP
13
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g
/m
l)
Normal
Preeclampsia
Unaffected
Table 2. PP13 MoM values throughout pregnancy
Weeks after 
LMP
Normal (n = 41) Unaffected (n = 59) Late-onset preeclampsia
median
PP13
MoM median
PP13
MoM PP13 raw data, No. median
PP13
MoM
149 63 117 129
5–10 292 (205–379) 1.00 (0.70–1.30) 180 (132–228)** 0.68 (0.50–0.18)** 29 36 34 50 35** 0.12 (0.08–0.16)**
11–15 306 (223–389) 1.00 (0.73–1.27) 248 (198–306)* 0.81 (0.75–1.25)* 71 16 34 57 46** 0.15 (0.08–0.22)*
16–20 313 (223–404) 1.00 (0.71–1.29) 268 (226–306) 0.86 (0.71–1.01) 110 137 156 160 147** 0.47 (0.39–0.55)*
21–25 329 (256–412) 1.00 (0.78–1.25) 282 (200–360) 0.86 (0.72–1.02) 284 259 265 265* 0.80 (0.73–0.87)
26–30 381 (302–460) 1.00 (0.84–1.16) 336 (376–396) 0.88 (0.68–1.22) 435 352 381 288 367 0.96 (0.82–1.10)
31–35 420 (352–488) 1.00 (0.83–1.21) 393 (323–353) 0.94 (0.85–1.05) 565 543 535 497 539* 1.23 (1.13–1.33)*
36–40 498 (424–572) 1.00 (0.85–1.15) 460 (383–537) 0.92 (0.81–1.03) 937 850 790 990 894** 1.79 (1.61–1.98)**
41–45 (PD) 305 (195–420) 1.00 (0.64–1.37) 291 (203–379) 0.95 (0.78–1.22) 573 550 480 560 529** 0.89 (0.63–1.05)
46–50 (PD) 45 (11–110) 1.00 (0.84–1.16) 57 (33–94) 1.26 (1.00–1.45) 86 134 182 134** 0.65 (0.40–0.95)
51–55 (PD) 23 (11–35) 1.00 (0.47–1.52) 13 (0–21.59) 0.59 (0.07–1.07) 6 15 14 50 15 0.65 (0.45–0.85)
Figures in parentheses are 95% CI. As weeks were counted from the last menstrual period, weeks 41–45, 46–50 and 51–55 after last menstrual period cor-
respond to 1–5, 6–10 and 11–15 weeks after delivery. PD stands for post delivery values. LMP = Last menstrual period. * p < 0.05; ** p < 0.005. PP13 raw data 
of 149, 63, 117 and 129 reflect values of individual patients who developed preeclampsia, identified by their study code.
b
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 Fig. 1.  a PP13 in patients’ serum through-
out pregnancy. Course of PP13 release into 
maternal blood in normal pregnant wom-
en (n = 41; solid line), in unaffected women 
(n = 59; triangles, no line) and in patients 
who developed late-onset preeclampsia at 
term (n = 4; dashed line). Each woman 
gave 10–12 blood samples after enrolment. 
Data are represented as medians with 95% 
CI of intervals of 2 weeks. Weeks are pre-
sented after last menstrual period. Ac-
cordingly, weeks 41–55 represent 1–15 
weeks after delivery.  b Comparative view 
on the time course of PP13 release (solid 
line; R 2 = 0.9677) relative to data published 
elsewhere  [17] showing growth of villous 
surface (dotted line; R 2 = 1.0) and growth 
of trophoblast volume (dashed line; R 2 = 
1.0) throughout gestation. For PP13, the y-
axis shows picogram of PP13 per milliliter 
of maternal peripheral serum, for villous 
surface, the y-axis shows square centime-
ters (original values  ! 3/1,000) and for tro-
phoblast volume, the y-axis shows cubic 
centimeters (original values  ! 5). The val-
ues for villous surface and trophoblast vol-
ume are taken from Mayhew and Barker 
 [17] . 
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time point of 7 weeks, there was no overlap between the 
individuals of the 2 groups and all normal cases were 
higher than preeclamptic patients. During the second 
trimester, the PP13 values in the preeclampsia cases grew 
to reach normal levels with medians at gestational age 
16–20, 21–25 and 26–30 weeks growing to 147, 265 and 
367 pg/ml, respectively (p  ! 0.04, 0.21 and 0.75, respec-
tively;  table 2 ). During the third trimester, PP13 values of 
the preeclamptic patients overshot above normal with 
medians at gestational age 31–35 and 36–40 weeks reach-
ing 539 and 894 pg/ml, respectively (p = 0.05 and 0.001, 
respectively;  table 2 ). In the preeclampsia group, PP13 
was elevated 7–15 times for each individual patient be-
tween the first and the third trimester, whereas average 
differences for the women of the normal outcome group 
were 1.4–2 times. After delivery, the values decreased 
back to normal and then completely disappeared, indi-
cating that serum PP13 is directly related to pregnancy 
and placenta ( table 2 ;  fig. 1 a).
 PP13 MoM 
 Based on medians at each gestational age of the nor-
mal outcome group, the corresponding MoM value was 
set to 1.0. For the late-onset preeclampsia group, the PP13 
MoM values were significantly lower than in the normal 
group at gestational age 5–10 and 11–15 weeks ( table 2 ). 
During the second trimester, MoM values were growing 
towards the normal level ( table 2 ). Third-trimester values 
reached above normal and became significantly different 
again ( table 2 ) when symptoms of preeclampsia were 
clinically evident. The change of MoM values for any pre-
eclampsia patient during the entire period reflected ini-
tial low MoM values at the period of risk assessment, 
growing gradually into very high MoM values during the 
outbreak of clinical symptoms of the pathology. After de-
livery, PP13 disappeared from the blood in all cases and 
controls. Values for the unaffected group were slightly 
but not significantly lower compared to the normal group 
( table 2 ).
 Immunohistochemistry 
 Immunohistochemical staining for PP13 in human 
term placentas revealed a clear and nearly exclusive 
staining of the apical membrane of the syncytiotropho-
blast ( fig. 2 a). With this staining, also the microvillous 
brush border became visible. In cases from late-onset 
preeclampsia, staining for PP13 revealed a similar pic-
ture ( fig. 2 b–d). Here, increased staining of the apical 
syncytial membrane was found and additional staining 
of fetal blood vessels was present ( fig. 2 b, asterisk). In 
the pathological cases, alterations of the apical mem-
brane became obvious, displaying structures that may 
lead to the necrotic release of syncytiotrophoblast mem-
brane fragments, known to be increased in preeclamp-
sia  [15] .
 Discussion 
 Limitations 
 This study was carried out with a relatively small co-
hort and compares 4 term preeclampsia cases with 59 
unaffected cases (41 with normal outcome). While the 
proportion of cases fits the size of the cohort, the discus-
sion takes into consideration that this is an initial obser-
vation that should stimulate the implementation of a 
larger cohort study. The limited number of cases is 
slightly misleading, since the longitudinal sampling of 
10–12 blood samples from each participant enabled us 
to gain a quite reliable view on the change over time for 
a
d
c
b
 Fig. 2. Immunohistochemistry for PP13 in 
placenta. A normal term placenta ( a ) and 2 
cases of late-onset preeclampsia cases ( b–
d ) stained for PP13. Note the more intense 
staining for PP13 in the preeclamptic cases 
especially at the apical membrane of the 
syncytiotrophoblast and additionally in 
fetal blood vessels (asterisk).  d The frame 
in  c has been enlarged to highlight the dis-
turbed surface of the syncytiotrophoblast 
showing evidence for necrotic release of 
subcellular fragments only in preeclamp-
sia (arrows).  a  ! 700.  b ,  c  ! 600.
 d  ! 800. 
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the normal outcome or the entire unaffected group. Ac-
cordingly, each preeclamptic case exhibits a strikingly 
different temporal change in the PP13 level compared to 
the unaffected group for any of the time points. The 
next step is of course associated with repeating the study 
on a larger scale, as included in the ongoing Pregenesys 
project.
 Correlation between PP13 Concentrations and 
Normal Development of the Placenta 
 Following the concentrations of PP13 in maternal pe-
ripheral venous serum, there is a slight reduction around 
the time of onset of maternal blood flow into the pla-
centa, that is, between weeks 9 and 13  [16] . After the es-
tablishment of maternal blood flow through the placen-
ta, there is a constant increase in PP13 in maternal blood 
until near term. It peaks at around 36 weeks and then 
slightly decreases until delivery. Afterwards, it disap-
pears within a week.  Figure 1 b shows the course of PP13 
throughout pregnancy in control women (same data as 
in  fig. 1 a, solid line) related to the course of other placen-
tal parameters that change during pregnancy: tropho-
blast volume and villous surface (data taken from May-
hew and Barker  [17] ). It becomes obvious that all 3 cours-
es display the lowest values at the transition from the first 
to the second trimester followed by a constant increase 
starting at around midgestation. Since PP13 is expressed 
in the syncytiotrophoblast outer membrane, it is tempt-
ing to speculate that the increase in PP13 nicely reflects 
the increase in villous surface extension during pregnan-
cy. Any disturbance of the villous surface in terms of 
surface area or surface integrity will have a direct impact 
on the amount of PP13 released into the maternal circu-
lation.
 Assessing Abnormal Placental Development Already 
in the First Trimester of Pregnancy and Allowing to 
Test Putative Preventive Therapeutic Interventions 
 The longitudinal measurements of PP13 throughout 
pregnancy provide a clear picture of the changes in PP13 
release in cases with late-onset preeclampsia. They start 
with a significantly lower release during the first trimes-
ter, cross the normal course at about 20 weeks and peak 
prior and during the time of clinical symptoms. With 
these characteristics, the release of PP13 is well suited to 
distinguish normal pregnancy from cases developing 
late-onset preeclampsia already during or at the end of 
the first trimester. This of course will be ameliorated if 
other factors will be evaluated in parallel as has been 
done for trisomy 21  [18] .
 Recently, 2 studies have been published concentrating 
on serum samples from the first trimester  [10, 11] . Both 
studies showed the same significant reduction of the 
PP13 levels irrespective of whether the woman developed 
an early- or a late-onset type of preeclampsia. Further-
more, 2 recent reviews described PP13 as one of the most 
promising markers to predict preeclampsia  [19, 20] .
 The longitudinal first trimester testing of PP13 helps 
strengthening the prediction of an elevated risk for a lat-
er development of preeclampsia and potentially identify-
ing a cutoff for this syndrome. In addition, the repeated 
testing throughout the second and third trimesters ap-
pears to enable differential diagnosis of the anticipated 
pathology based on the slope of change between consecu-
tive measurements, such as differentiating between early- 
and late-onset preeclampsia.
 The biphasic changes in the release of PP13 in pre-
eclampsia compared to control cases raises the question 
as to how these alterations can be explained. The signifi-
cantly lower values in the first trimester may find their 
explanation in an abnormal development of the placenta 
already at this stage of pregnancy. Although there are hy-
potheses that claim that these alterations should occur 
very early during placental development, so far no proof 
for such changes have been presented. The changes in 
PP13 release may be a first indicator of a dysregulated 
placental development early in pregnancy resulting in 
preeclampsia. It has to be noted though, that the reduced 
amounts of PP13 are true for both groups of preeclamp-
sia, early as well as late onset [ 10, 11 , this study], while a 
general explanation for these very low levels early in ges-
tation is missing.
 The overshoot of PP13 prior to and during the onset of 
clinical symptoms of preeclampsia is much easier to ex-
plain. It has been shown that trophoblast apoptosis is in-
creased in preeclampsia  [21] . Since apoptotic material is 
cleared in the lungs of pregnant women and will not re-
sult in activation of the maternal inflammatory system 
 [22] , and since elevated apoptosis has also been described 
for IUGR  [23] , increased apoptosis cannot account for the 
increase in PP13 in preeclampsia. On the other hand, it 
has been postulated  [24] that it is rather an increase in the 
rates of necrosis and aponecrosis that may account for the 
increase in proteins and DNA in peripheral blood as well 
as account for the induction of the inflammatory re-
sponse. This hypothesis is supported by a recent paper by 
Goswami et al.  [25] , who showed that subcellular frag-
ments of the syncytiotrophoblast inside maternal blood 
are only elevated in preeclampsia but not in IUGR.
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 Conclusions 
 Testing of PP13 in maternal blood throughout preg-
nancy may enable us to view a proper placental develop-
ment. Alterations of placental structure and function 
may be directly related to changes in the amount of PP13 
released into maternal blood. Since such alterations can 
be visualized already during the course of the first tri-
mester in pregnancy pathologies where a placental cause 
is expected, PP13 may be used as a tool to assess an ab-
normal development of the placenta in preeclampsia.
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